Moneycontrol PRO
Check Credit Score
Check Credit Score
HomeNewsBusiness

Eyeing over 80% sales from US, India, Europe by 2021: Glenmark

As part of its medium term strategy, the company is also looking at increasing presence in complex generics, Glenmark said in a presentation to be made at the J P Morgan Healthcare Conference in the US, as per its BSE filing.

January 10, 2018 / 02:38 PM IST
Aurobindo Pharma Ltd.

Aurobindo Pharma Ltd.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Glenmark Pharmaceuticals today said it expects the US, Indian and European markets, along with active pharmaceutical ingredient (API) segment, to contribute over 80 per cent to its sales by 2021.

As part of its medium term strategy, the company is also looking at increasing presence in complex generics, Glenmark said in a presentation to be made at the J P Morgan Healthcare Conference in the US, as per its BSE filing.

The company is also planning to scale up its speciality business in the US as part of its future outlook for 2021, it added. In next three to five years, the new molecular entity (NME) pipeline will be in advanced stages of development, Glenmark said.

For the company, core therapy areas are oncology, dermatology and respiratory segments. It also aims to have a global manufacturing footprint by 2021, it added. The profitability margin which was at 20 per cent in 2017 will be at 23 per cent in 2021.

The company is looking at a profitability margin of 25 per cent in 2025, Glenmark said. "Speciality and innovative segments to be the main growth drivers in 2025," it added.

PTI
first published: Jan 10, 2018 02:35 pm

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347